Targeting Vitamin D Deficiency to Limit Exacerbations in Respiratory Diseases: Utopia or Strategy With Potential?
Karen MaesJef SerréCarolien MathyssenWim JanssensGhislaine Gayan-RamirezPublished in: Calcified tissue international (2019)
Patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or asthma often experience an acute worsening of respiratory symptoms, termed exacerbations. Although the course of exacerbations is disease specific, they are mostly triggered by a respiratory infection. Exacerbations often require hospitalization and are an important cause of mortality. Treatments of exacerbations aim to minimize the negative impact and to prevent subsequent events. Despite many existing therapy options, many patients do not benefit from therapy and suffer from recurrent events. Vitamin D deficiency is a worldwide problem and is extremely prevalent in these patients. Vitamin D, known for its calcemic effects, also has immunomodulatory and anti-infectious actions and can therefore be a possible agent to treat or prevent exacerbations. This review will focus on vitamin D as a potential candidate to treat or prevent exacerbations in CF, COPD, and asthma.
Keyphrases
- chronic obstructive pulmonary disease
- cystic fibrosis
- lung function
- end stage renal disease
- chronic kidney disease
- pseudomonas aeruginosa
- newly diagnosed
- ejection fraction
- type diabetes
- prognostic factors
- stem cells
- hepatitis b virus
- physical activity
- cardiovascular disease
- coronary artery disease
- depressive symptoms
- mechanical ventilation
- drug delivery
- patient reported
- sleep quality
- bone marrow
- smoking cessation
- climate change
- respiratory failure
- acute respiratory distress syndrome
- replacement therapy
- cancer therapy